ASAM patient placement criteria definition

ASAM patient placement criteria means the American Society of Addiction Medicine's Patient Placement Criteria for the Treatment of Substance-Related Disorders, Fourth Edition (ASAMPPC-2R), 4601 North Park Avenue, Upper Arcade Suite 101, Chevy Chase MD 20815 (2001, no later amendments or editions included).
Sample 1Sample 2Sample 3
ASAM patient placement criteria means the third edition, revised, of the patient placement criteria of the American society of addiction medicine.
Sample 1Sample 2
ASAM patient placement criteria or "ASAM PPC" means the most current edition of the American Society of Addiction Medicine's published criteria for admission to treatment, continued services, and discharge.
Sample 1

Examples of ASAM patient placement criteria in a sentence

  • A&D 67 Services provide a structured environment for an Individual on a 24-hour basis consistent with Level II and Level III of the American Society of Addiction Medicine (ASAM) patient placement criteria and transfer and continuity of care set forth in OAR 309-018-0135 through 309-018-0155 and 309-019-0135 through 309-019- 0140, as such rules may be revised from time to time, are appropriate to the Individual’s needs and include housing and food services.

  • Where possible, all covered services are in alignment with the American Society for Addiction Medicine (ASAM) patient placement criteria.

  • Further, all payors utilize various utilization management approaches to ensure appropriate levels of care are accessed for individual treatment needs.Future State:IDHW will align service definitions and placement criteria with national evidence-based definitions, particularly for newly added inpatient and residential services in IMDs. Specifically, tor SUD treatment services, IDHW will utilize the ASAM patient placement criteria, the most widely accepted and comprehensive set of guidelines.

  • In addition, the DHCFP utilizes American Society of Addiction Medicine (ASAM) patient placement criteria to establish guidelines for level of care placements within the substance abuse continuum.

  • Although the terms “partial hospitalization,” “day treatment,” and “intensive outpatient” programs may be used nearly in- terchangeably in different parts of the country, the ASAM patient placement criteria (39) de- fine structured programming in partial hospitalization programs as 20 hours per week and in intensive outpatient programs as 9 hours per week.

  • According to ASAM's website, the ASAM criteria, formerly known as the ASAM patient placement criteria, is the result of a collaboration that began in the 1980s to define one national set of criteria for providing outcome-oriented and results-based care in the treatment of addiction.

  • He holds a bachelor’s degree in business administration from San Francisco State University and a master’s in nonprofit administration from the University of San Francisco.Mr. Porter volunteers in support of public education and health care and has served on numerous board of directors, including Washington Yu Ying and Two Rivers public charter schools, both in Washington, D.C.; and Chase Brexton Health Care services in Maryland.

  • A&D 67 Services provide a structured environment for an Individual on a 24-hour basis consistent with Level II and Level III of the American Society of Addiction Medicine (ASAM) patient placement criteria and transfer and continuity of care set forth in OAR 309-018-0135 through 309- 018-0155 and 309-019-0135 through 309-019-0140, as such rules may be revised from time to time, are appropriate to the Individual’s needs and include housing and food services.

  • Outpatient youth group and Intensive Outpatient youth group therapy.o Women who are pregnant or postpartum (up to one year past delivery, regardless of birth outcome, adoption or foster care placement of child) and women with dependent children. Youth, adult, and PPW Case Management (ASAM Levels 1 or 2) Youth, adult, and PPW assessment: Costs incurred in diagnosis, placement in accordance with the American Society of Addiction Medicine (ASAM) patient placement criteria.

  • Service access is exclusively managed by CSOC’s Contracted System Administrator (CSA), and clinical criteria for service is based on the American Society of Addiction Medicine (ASAM) patient placement criteria.


More Definitions of ASAM patient placement criteria

ASAM patient placement criteria means the criteria developed by the American Society of Addiction Medicine, contained in “Patient Placement Criteria for the Treatment of Substance Related Disorder,” 2d
Sample 1
ASAM patient placement criteria means the American Society of Addiction Medicine's published criteria for admission to treatment, continued services and discharge.
Sample 1

Related to ASAM patient placement criteria

  • Additional Indication means any indication other than the Initial Indication.

  • Monitoring Indicator means a measure of HSP performance that may be monitored against provincial results or provincial targets, but for which no Performance Target is set;

  • Clinical nurse specialist means a registered nurse with relevant post-basic qualifications and 12 months’ experience working in the clinical area of his/her specified post-basic qualification, or a minimum of four years’ post-basic registration experience, including three years’ experience in the relevant specialist field and who satisfies the local criteria.

  • MSAA Indicator Technical Specifications document means, as the context requires, either or both of the document entitled “Multi-Sector Service Accountability Agreement (MSAA) 2019-20 Indicator Technical Specifications November 5, 2018 Version 1.3” and the document entitled “Multi-Sector Service Accountability Agreement (MSAA) 2019-20 Target and Corridor-Setting Guidelines” as they may be amended or replaced from time to time;

  • Phase 2 Clinical Trial means a human clinical trial, for which the primary endpoints include a determination of dose ranges or an indication of efficacy in patients being studied as described in 21 C.F.R. §312.21(b), or an equivalent clinical trial in a country in the Territory other than the United States.

  • Approved clinical trial means a phase I, phase II, phase III, or phase IV clinical trial that is conducted in relation to the prevention, detection, or treatment of cancer or other life-threatening disease or Condition and is described in any of the following:

  • Phase 4 Clinical Trial means a Clinical Trial of a Product conducted after Regulatory Approval of such Product has been obtained from an appropriate Regulatory Authority, which trial is (a) conducted voluntarily by a Party to enhance marketing or scientific knowledge of the Product, or (b) conducted due to a request or requirement of a Regulatory Authority.

  • Collaborative pharmacy practice agreement means a written and signed

  • Secondary dose monitoring system means a system which will terminate irradiation in the event of failure of the primary dose monitoring system.

  • Reference biological product means the single biological product licensed pursuant to 42 U.S.C.

  • Medical marijuana product means a product that contains cannabinoids that have been extracted from plant material or the resin therefrom by physical or chemical means and is intended for administration to a licensed patient, including but not limited to concentrates, oils, tinctures, edibles, pills, topical forms, gels, creams, and other derivative forms, except that this term does not include live plant forms.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Phase I Clinical Study means a human clinical study of a product, the principal purpose of which is a preliminary determination of safety in healthy individuals or patients, as described in 21 C.F.R. 312.21(a).

  • Back Ordered Products If product is not expected to ship within the time provided to the TIPS Member by the Vendor, the Member is to be notified within 3 business days and appropriate action taken based on customer request. TIPS Vendor Agreement Signature Form RFP 200401 Food Service Equipment, Chemicals, Supplies and Services Parts Town, LLC dba Heritage Food Service Group, LLC Company Name Address 0000 Xxxxxxxxx Xxxx City Fort Xxxxx State IN Zip 46808 Phone 000-000-0000 Fax 000-000-0000 Email of Authorized Representative XxxxxxxxXxxxxxxx@xxxx.xxx Name of Authorized Representative Xxxx Xxxxxx Title Customer Service Manager Signature of Authorized Representative 5/1/2020 TIPS Authorized Representative Name TIPS Authorized Representative Signature Approved by ESC Region 8 Date пͿлмͿлйлй TIPS VENDORS RESPOND TO ATTRIBUTE QUESTIONS AS PART OF TIPS COMPETITIVE SOLICITATION PROCESS. THE VENDOR’S RESPONSES TO ATTRIBUTE QUESTIONS ARE INCLUDED HEREIN AS “SUPPLIER RESPONSE.” PLEASE BE ADVISED THAT DEVIATIONS, IF ANY, IN VENDOR’S RESPONSE TO ATTRIBUTE QUESTIONS MAY NOT REFLECT VENDOR’S FINAL ATTRIBUTE RESPONSE, WHICH IS SUBJECT TO NEGOTIATIONS PRIOR TO AWARD. PLEASE CONTACT THE TIPS OFFICE AT 866-839- 8477 WITH QUESTIONS OR CONCERNS REGARDING VENDOR ATTRIBUTE RESPONSE DEVIATIONS. PLEASE KEEP IN MIND THAT TIPS DOES NOT PROVIDE LEGAL COUNSEL TO MEMBERS. TIPS RECOMMENDS THAT YOU CONSULT YOUR LEGAL COUNSEL WHEN EXECUTING CONTRACTS WITH OR MAKING PURCHASES FROM TIPS VENDORS. Number: 200401 Addendum 1 Title: Food Service Equipment, Chemicals, Supplies and Services Type: Request for Proposal Issue Date: 4/2/2020 Deadline: 5/15/2020 03:00 PM (CT) Address: Region 8 Education Service Center 0000 XX Xxxxxxx 000 Xxxxx Xxxxxxxxx, XX 00000 Phone: +0 (000) 000-0000 Email: xxxx@xxxx-xxx.xxx Address: 0000 Xxxxxxxxx Xxxx Xxxx Xxxxx, IN 46808 Phone: (000) 000-0000 Fax: (000) 000-0000 Toll Free: (000) 000-0000 By submitting your response, you certify that you are authorized to represent and bind your company.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Therapeutic diet means meals served that are soft, low-fat, low-sodium or controlled calorie.

  • Therapeutic Product means a health product categorised as a therapeutic product in the First Schedule to the Act;

  • Participating Certified Clinical Nurse Specialist means a Certified Clinical Nurse Specialist who has a written agreement with the Claim Administrator or another Blue Cross and/or Blue Shield Plan to provide services to you at the time services are rendered.

  • Program Parameter means, in respect of a program, the provincial standards (such as operational, financial or service standards and policies, operating manuals and program eligibility), directives, guidelines and expectations and requirements for that program;

  • medicinal product means any substance or combination of substances presented for treating or preventing disease in human beings or animals and any substance or combination of substances which may be administered to human beings or animals with a view to making a medical diagnosis or to restoring, correcting or modifying physiological functions in humans or in animals;

  • Peer support specialist means an individual who has experienced a severe and persistent mental illness and who has successfully completed standardized training to provide peer support services through the medical assistance program or the Iowa Behavioral Health Care Plan.

  • Direction-indicator lamp means the lamp used to indicate to other road-users that the driver intends to change direction to the right or to the left;

  • Medical Specialist means any medical practitioner who is vocationally registered by the Medical Council under the Health Practitioners Competence Assurance Act 2003 in one of the approved branches of medicine and who is employed in either that branch of medicine or in a similar capacity with minimal oversight.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Active Pharmaceutical Ingredient or “API” shall mean one or more of the following active pharmaceutical ingredients: tenofovir alafenamide (“TAF”), tenofovir disoproxil fumarate (“TDF”), elvitegravir (“EVG”), and cobicistat (“COBI”).